Esketamine
Medication used for treatment-resistant depression
Esketamine | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | Nasal spray |
Pregnancy category | |
Bioavailability | |
Metabolism | Liver (CYP2B6, CYP3A4) |
Elimination half-life | 7-12 hours |
Excretion | Urine |
Legal status | |
CAS Number | 33643-46-8 |
PubChem | 123631 |
DrugBank | DB01221 |
ChemSpider | 110146 |
KEGG | D09373 |
Esketamine, sold under the brand name Spravato, is a medication used for the treatment of treatment-resistant depression (TRD). It is a stereoisomer of ketamine, specifically the S(+) enantiomer. Esketamine is administered as a nasal spray and works as a NMDA receptor antagonist.
Medical uses
Esketamine is primarily used for treatment-resistant depression in adults who have not responded adequately to at least two different antidepressant treatments. It is often used in conjunction with an oral antidepressant.
Mechanism of action
Esketamine acts as a NMDA receptor antagonist, which is believed to contribute to its rapid antidepressant effects. By blocking the NMDA receptor, esketamine increases the levels of glutamate in the brain, which in turn activates AMPA receptors and leads to the release of brain-derived neurotrophic factor (BDNF). This cascade of events is thought to contribute to the synaptic plasticity and antidepressant effects observed with esketamine.
Side effects
Common side effects of esketamine include dissociation, dizziness, nausea, sedation, vertigo, and increased blood pressure. Due to its potential for abuse and dissociative effects, esketamine is classified as a Schedule III controlled substance in the United States.
History
Esketamine was approved by the U.S. Food and Drug Administration (FDA) in March 2019 for the treatment of treatment-resistant depression. It was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD